BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Richardt-Pargmann D, Vollmer J. Stimulation of the immune system by therapeutic antisense oligodeoxynucleotides and small interfering RNAs via nucleic acid receptors. Ann N Y Acad Sci 2009;1175:40-54. [PMID: 19796076 DOI: 10.1111/j.1749-6632.2009.04971.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Frazier KS, Obert LA. Drug-induced Glomerulonephritis: The Spectre of Biotherapeutic and Antisense Oligonucleotide Immune Activation in the Kidney. Toxicol Pathol 2018;46:904-17. [PMID: 30089413 DOI: 10.1177/0192623318789399] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
2 Slijkerman RW, Vaché C, Dona M, García-García G, Claustres M, Hetterschijt L, Peters TA, Hartel BP, Pennings RJ, Millan JM, Aller E, Garanto A, Collin RW, Kremer H, Roux AF, Van Wijk E. Antisense Oligonucleotide-based Splice Correction for USH2A-associated Retinal Degeneration Caused by a Frequent Deep-intronic Mutation. Mol Ther Nucleic Acids 2016;5:e381. [PMID: 27802265 DOI: 10.1038/mtna.2016.89] [Cited by in Crossref: 81] [Cited by in F6Publishing: 85] [Article Influence: 11.6] [Reference Citation Analysis]
3 van Meer L, Moerland M, Gallagher J, van Doorn MB, Prens EP, Cohen AF, Rissmann R, Burggraaf J. Injection site reactions after subcutaneous oligonucleotide therapy. Br J Clin Pharmacol 2016;82:340-51. [PMID: 27061947 DOI: 10.1111/bcp.12961] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
4 Engelhardt JA, Fant P, Guionaud S, Henry SP, Leach MW, Louden C, Scicchitano MS, Weaver JL, Zabka TS, Frazier KS; Society of Toxicologic Pathology Vascular Injury Working Group. Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part 2. Antisense Oligonucleotides. Toxicol Pathol 2015;43:935-44. [PMID: 25717082 DOI: 10.1177/0192623315570341] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
5 Frazier KS. Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective. Toxicol Pathol 2015;43:78-89. [PMID: 25385330 DOI: 10.1177/0192623314551840] [Cited by in Crossref: 179] [Cited by in F6Publishing: 185] [Article Influence: 19.9] [Reference Citation Analysis]
6 Frazier KS, Sobry C, Derr V, Adams MJ, Besten CD, De Kimpe S, Francis I, Gales TL, Haworth R, Maguire SR, Mirabile RC, Mullins D, Palate B, Doorten YP, Ridings JE, Scicchitano MS, Silvano J, Woodfine J. Species-specific inflammatory responses as a primary component for the development of glomerular lesions in mice and monkeys following chronic administration of a second-generation antisense oligonucleotide. Toxicol Pathol 2014;42:923-35. [PMID: 24292388 DOI: 10.1177/0192623313505781] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
7 Moschos SA, Spink KG, Lindsay MA. Measuring the Action of CPP–siRNA Conjugates in the Lung. Methods in Molecular Biology 2011. [DOI: 10.1007/978-1-60761-919-2_30] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]